TIDMRXB
Rex Bionics PLC
24 October 2016
Rex Bionics Plc
("Rex Bionics" or the "Company")
REX Stroke and Brain Injury Clinical Trial in Australia
24 October 2016: Rex Bionics Plc (AIM: RXB), the pioneer of the
REX Robot technology that enhances the mobility of wheelchair
users, is pleased to announce the start of a new clinical trial
treating patients who have had a stroke or brain injury, with
Robot-Assisted Physiotherapy with REX.
The trial is being conducted by the Australian Institute of
Neuro-rehabilitation, Nelson Bay, New South Wales (NSW), Australia
and the University of Newcastle, NSW; and is supported by The
Newcastle Permanent Charitable Foundation and Rex Bionics plc. The
trial has received ethics clearance through the Hunter New England
Human Research Ethics Committee (Ref: 16/08/17/4.06) and will be
carried out according to the standards of the National Health and
Medical Research Council of Australia.
The trial will recruit volunteers from the Hunter Region of NSW,
who have had a stroke or head injury more than three months
previously and have difficulty standing and walking. Volunteers
will be treated twice a week for twelve weeks and the REX treatment
will be supplemented by a home programme of exercises. There is
provision for MRI examination to correlate the functional and
neurological response to treatment.
More than one-third of people who survive a stroke or head
injury need help in walking and some will never regain the ability
to stand without assistance. This affects the patient's ability to
participate in rehabilitation, their long term health, and the
ability to do social, work and leisure activities.
There are more than 420,000 people living with the effects of
stroke in Australia and 30% of these people are of working age. 65%
of those living with stroke also suffer a disability that impedes
their ability to carry out daily living activities unassisted. In
2012, the total financial costs of stroke in Australia were
estimated to be A$5 billion.
Trish Leonard, the Founder of AIN, commented: "In REX's
self-supporting exoskeleton we see the potential to provide greater
opportunities for weight bearing exercises to people with stroke
and other acquired brain injuries. We are excited to be involved in
ground breaking research to evaluate REX's robotic exercise therapy
as a neuro-rehabilitation tool"
Crispin Simon, Chief Executive of Rex Bionics plc added:
"Congratulations to AIN and their partners on being the first
clinical research group to establish a trial using REX to treat
stroke and brain injury. It is exciting to consider the possibility
of functional improvement in a condition, like stroke, where so
many people live with a severely compromised quality of life."
A copy of this announcement has been posted on the Company's
website at www.rexbionics.com.
For further information please contact:
Rex Bionics Plc
Crispin Simon, Chief Executive Officer
+44 (0) 781 086 6386
Stifel Nicolaus Europe Limited (NOMAD and Broker)
Jonathan Senior/ Stewart Wallace / Ben Maddison
+44 (0) 20 7710 7600
Consilium Strategic Communications
Mary-Jane Elliott / Chris Welsh
rexbionics@consilium-comms.com
+44 (0) 203 709 5700
About the Hunter Region
The Hunter Region, also commonly known as the Hunter Valley, is
a region of New South Wales, Australia, extending from
approximately 75 miles to 195 miles north of Sydney.
About REX at AIN
The REX robot is known locally as HELLEN (Hunter's Exoskeleton
for Lower Limb Exercise and Rehabilitation).
About Rex Bionics Plc
Rex Bionics is the pioneer of the "REX" that provides robotic
standing, walking and exercise support for wheelchair users; and
was founded by two British engineers with first-hand experience of
the needs of wheelchair users. REX is used by people who have
suffered a spinal cord injury, stroke or other traumatic brain
injury; and people with multiple sclerosis, muscular dystrophy and
cerebral palsy.
We are working with physiotherapists to develop the concept and
practice of Robot-Assisted Physiotherapy (RAP); and also offer REX
P, for use in the home, enabling customers to walk and stand with
their hands free - providing more work and recreation options.
Wheelchair users are at risk of developing numerous medical
complications from extended periods of sitting. By enabling them to
spend more time standing, walking and exercising, REX may offer
significant health benefits, including improved sleep and
maintenance of joint range, and a reduction in spasm, pain, common
abdominal problems and prescription drug use.
Our commitment to engineering excellence is complemented by a
commitment to clinical science and the RAPPER II clinical trial
results show high levels of practicality, safety and user
enthusiasm.
Our Vision is that every day, around the world, thousands of
people get relief with REX, from the harm - the pain, discomfort
and inconvenience - of neurological accidents and illnesses; and
that many will be cured.
Rex Bionics was admitted to trading on the London Stock
Exchange's AIM in 2014. REX is not registered for At-Home use in
the United States of America.
Enquiries to (info@rexbionics.com)
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRALFFILIDLVFIR
(END) Dow Jones Newswires
October 24, 2016 02:00 ET (06:00 GMT)
Rex Bionics (LSE:RXB)
Historical Stock Chart
Von Mai 2024 bis Jun 2024
Rex Bionics (LSE:RXB)
Historical Stock Chart
Von Jun 2023 bis Jun 2024